Liquid Biopsy of Breast Cancer Update with Founder of Savran Tech.

Sponsored by: Purdue University entrepreneurship Peter Fasse, patent attorney at Fish & Richardson In December of 2017 I interviewed Çağrı Savran, Ph.D. about plans for his startup in which I had just invested. Almost four years later I interviewed him again to review the progress of the company which is changing the way breast cancer is followed up after treatment. Highlights: Update on the Original Interview with Çağrı Savran, Ph.D. In December of 2017 Savran Was Operating with Essential Components Handmade in the Lab – In October 2021 the Main Components Are Produced by a Vendor Early Technology Was Used in a Major Clinical Trial at Indiana University School of Medicine and Significantly Improved Prediction of Recurrence of a Breast Cancer The Existing Technology for Capturing Circulating Tumor Cells Is Not Scalable – Savran's Tech Is Amenable to Scale Strategic Players in Prenatal Diagnostics Are Interested in Sequencing the Cells Captured – Savran Is Uniquely Positioned to Provide That Ability The Basic Technology Is Like a Kitchen, the Different Assays Are Like What's Being Prepared in the Kitchen Savran Has Recruited a Capable and Involved Board Sal Daher Summarizes Savran's Progress in the Last Four Years